Eli Lilly and Atomwise have joined forces to use AI in drug discovery. They will collaborate to test up to 10 development targets selected by Eli Lilly. The partnership will use Atomwise’s AI-driven structure-based small molecule drug discovery technology AtomNet, which is already being used in 19 countries. The typical hit rate also is 10,000 times more accurate, he explained. As part of the deal Atomwise could earn up to $1m for discovery milestones and up to $550m for milestones in development and commercialisation. “Today’s announcement marks a significant milestone on our journey towards bringing artificial intelligence (AI) into pharma,” said Dr. David Sinclair, CEO of Atomwise.
Eli Lilly and Atomwise have joined forces to use AI in drug discovery. They will collaborate to test up to 10 development targets selected by Eli Lilly. The partnership will use Atomwise’s AI-driven structure-based small molecule drug discovery technology AtomNet, which is already being used in 19 countries. As part of the deal Atomwise could earn up to $1m for discovery milestones and up to $550m for milestones in development and commercialisation. “Today’s announcement marks a significant milestone on our journey towards bringing artificial intelligence (AI) into pharma,” said Dr. David Sinclair, CEO of Atomwise.